ScAAVIL-1ra dosing trial in a large animal model and validation of long-term expression with repeat administration for osteoarthritis therapy

Gene Therapy

Volumn 22, Issue 7, 2015, Pages 536-545

  Goodrich, L R ^a   Grieger, J C ^b   Phillips, J N ^a   Khan, N ^b   Gray, S J ^b   McIlwraith, C W ^a   Samulski, R J ^b  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; GREEN FLUORESCENT PROTEIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; NEUTRALIZING ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; CARTILAGE; CONTROLLED STUDY; DRUG DISTRIBUTION; ENZYME LINKED IMMUNOSORBENT ASSAY; EQUINE MODEL; HEART; HORSE; IMMUNE RESPONSE; JOINT BIOPSY; KIDNEY; LARGE INTESTINE; LEUKOCYTE; LIVER; LUNG; MAXILLARY NERVE; MUSCLE; NONHUMAN; OSTEOARTHRITIS; OVARY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SALIVARY GLAND; SPINAL CORD; SPLEEN; SYNOVIUM; THYMUS; THYROID GLAND; UTERUS; ADMINISTRATION AND DOSAGE; ANIMAL; ARTICULAR CARTILAGE; CARPAL JOINT; DISEASE MODEL; DOSE RESPONSE; GENE EXPRESSION; GENE THERAPY; GENE VECTOR; GENETICS; IMMUNOLOGY; METABOLISM; PATHOLOGY; THERAPEUTIC USE;

ANIMALIA; EQUIDAE; MIRIDAE;

ANIMALS; ANTIBODIES, NEUTRALIZING; CARPAL JOINTS; CARTILAGE, ARTICULAR; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; GENE EXPRESSION; GENETIC THERAPY; GENETIC VECTORS; HORSES; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; OSTEOARTHRITIS; SYNOVIAL MEMBRANE;

EID: 84934437809     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2015.21     Document Type: Article

References (59)

1. McAlindon TE, Bannuru RR, Sullivan MC, Arden NK, Berenbaum F, Bierma-Zeinstra SM et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage 2014; 22: 363-388.
2. Ishijima M, Nakamura T, Shimizu K, Hayashi K, Kikuchi H, Soen S et al. Intraarticular hyaluronic acid injection versus oral non-steroidal anti-inflammatory drug for the treatment of knee osteoarthritis: a multi-center, randomized, openlabel, non-inferiority trial. Arthritis Res Ther 2014; 16: R18.
3. Frisbie DD, Kawcak CE, McIlwraith CW, Werpy NM. Evaluation of polysulfated glycosaminoglycan or sodium hyaluronan administered intra-articularly for treatment of horses with experimentally induced osteoarthritis. Am J Vet Res 2009; 70: 203-209.
4. Frisbie DD, Kawcak CE, Trotter GW, Powers BE, Walton RM, McIlwraith CW. Effects of triamcinolone acetonide on an in vivo equine osteochondral fragment exercise model. Equine Vet J 1997; 29: 349-359.
5. Baltzer AW, Moser C, Jansen SA, Krauspe R. Autologous conditioned serum (Orthokine) is an effective treatment for knee osteoarthritis. Osteoarthritis Cartilage 2009; 17: 152-160.
6. Abate M, Schiavone C, Salini V. Hyaluronic acid in ankle osteoarthritis: why evidence of efficacy is still lacking? Clin Exp Rheumatol 2012; 30: 277-281.
7. Nigrovic PA, Mannion M, Prince FH, Zeft A, Rabinovich CE, van Rossum MA et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathicarthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 2011; 63: 545-555.
8. Yang KG, Raijmakers NJ, van Arkel ER, Caron JJ, Rijk PC, Willems WJ et al. Autologous interleukin-1 receptor antagonist improves function and symptoms in osteoarthritis when compared to placebo in a prospective randomized controlled trial. Osteoarthritis Cartilage 2008; 16: 498-505.
9. Frisbie DD, Kawcak CE, Werpy NM, Park RD, McIlwraith CW. Clinical, biochemical, and histologic effects of intra-articular administration of autologous conditioned serum in horses with experimentally induced osteoarthritis. Am J Vet Res 2007; 68: 290-296.
10. Kraus VB, Birmingham J, Stabler TV, Feng S, Taylor DC, Moorman CT 3rd et al. Effects of intraarticular IL1-Ra for acute anterior cruciate ligament knee injury: a randomized controlled pilot trial (NCT00332254). Osteoarthritis Cartilage 2012; 20: 271-278.
11. Arend WP, Welgus HG, Thompson RC, Eisenberg SP. Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist. J Clin Investig 1990; 85: 1694-1697.
12. Daheshia M, Yao JQ. The interleukin 1beta pathway in the pathogenesis of osteoarthritis. J Rheumatol 2008; 35: 2306-2312.
13. Pelletier JP, McCollum R, Cloutier JM, Martel-Pelletier J. Synthesis of metalloproteases and interleukin 6 (IL-6) in human osteoarthritic synovial membrane is an IL-1 mediated process. J Rheumatol Suppl 1995; 43: 109-114.
14. Saha N, Moldovan F, Tardif G, Pelletier JP, Cloutier JM, Martel-Pelletier J. Interleukin-1beta-converting enzyme/caspase-1 in human osteoarthritic tissues: localization and role in the maturation of interleukin-1beta and interleukin-18. Arthritis Rheum 1999; 42: 1577-1587.
15. Smith MD, Triantafillou S, Parker A, Youssef PP, Coleman M. Synovial membrane inflammation and cytokine production in patients with early osteoarthritis. J Rheumatol 1997; 24: 365-371.
16. Kubota E, Imamura H, Kubota T, Shibata T, Murakami K. Interleukin 1 beta and stromelysin (MMP3) activity of synovial fluid as possible markers of osteoarthritis in the temporomandibular joint. J Oral Maxillofac Surg 1997; 55: 20-27; discussion 27-28.
17. Loeser RF, Carlson CS, Del Carlo M, Cole A. Detection of nitrotyrosine in aging and osteoarthritic cartilage: Correlation of oxidative damage with the presence of interleukin-1beta and with chondrocyte resistance to insulin-like growth factor 1. Arthritis Rheum 2002; 46: 2349-2357.
18. Baltzer AW, Ostapczuk MS, Stosch D, Seidel F, Granrath M. A new treatment for hip osteoarthritis: clinical evidence for the efficacy of autologous conditioned serum. Orthop Rev (Pavia) 2013; 5: 59-64.
19. Evans CH, Ghivizzani SC, Robbins PD. Arthritis gene therapy and its tortuous path into the clinic. Transl Res 2013; 161: 205-216.
20. Evans CH, Ghivizzani SC, Robbins PD. Getting arthritis gene therapy into the clinic. Nat Rev Rheumatol 2011; 7: 244-249.
21. Mease PJ, Wei N, Fudman EJ, Kivitz AJ, Schechtman J, Trapp RG et al. Safety, tolerability, and clinical outcomes after intraarticular injection of a recombinant adeno-associated vector containing a tumor necrosis factor antagonist gene: results of a phase 1/2 Study. J Rheumatol 2010; 37: 692-703.
22. Kay JD, Gouze E, Oligino TJ, Gouze JN, Watson RS, Levings PP et al. Intra-articular gene delivery and expression of interleukin-1Ra mediated by self-complementary adeno-associated virus. J Gene Med 2009; 11: 605-614.
23. Goodrich LR, Choi VW, Carbone BA, McIlwraith CW, Samulski RJ. Ex vivo serotypespecific transduction of equine joint tissue by self-complementary adeno-associated viral vectors. Hum Gene Ther 2009; 20: 1697-1702.
24. Goodrich LR, Phillips JN, McIlwraith CW, Foti SB, Grieger JC, Gray SJ et al. Optimization of scAAVIL-1ra in vitro and in vivo to deliver high levels of therapeutic protein for treatment of osteoarthritis. Mol Ther Nucleic Acids 2013; 2: e70.
25. Mason JB, Gurda BL, Engiles JB, Hankenson KD, Wilson JM, Richardson DW. Multiple recombinant adeno-associated viral vector serotypes display persistent in vivo gene expression in vector-transduced rat stifle joints. Hum Gene Ther Methods 2013; 24: 185-194.
26. Mason JB, Vandenberghe LH, Xiao R, Wilson JM, Richardson DW. Influence of serotype, cell type, tissue composition, and time after inoculation on gene expression in recombinant adeno-associated viral vector-transduced equine joint tissues. Am J Vet Res 2012; 73: 1178-1185.
27. Frisbie DD, Cross MW, McIlwraith CW. A comparative study of articular cartilage thickness in the stifle of animal species used in human pre-clinical studies compared to articular cartilage thickness in the human knee. Vet Comp Orthop Traumatol 2006; 19: 142-146.
28. McIlwraith CW, Frisbie DD, Kawcak CE. The horse as a model of naturally occurring osteoarthritis. Bone Joint Res 2012; 1: 297-309.
29. Vandenberghe LH, Wilson JM. AAV as an immunogen. Curr Gene Ther 2007; 7: 325-333.
30. Li C, Diprimio N, Bowles DE, Hirsch ML, Monahan PE, Asokan A et al. Single amino acid modification of adeno-associated virus capsid changes transduction and humoral immune profiles. J Virol 2012; 86: 7752-7759.
31. Ishihara A, Bartlett JS, Bertone AL. Inflammation and immune response of intraarticular serotype 2 adeno-associated virus or adenovirus vectors in a large animal model. Arthritis 2012; 2012: 735472.
32. Cottard V, Valvason C, Falgarone G, Lutomski D, Boissier MC, Bessis N. Immune response against gene therapy vectors: influence of synovial fluid on adenoassociated virus mediated gene transfer to chondrocytes. J Clin Immunol 2004; 24: 162-169.
33. Boissier MC, Lemeiter D, Clavel C, Valvason C, Laroche L, Begue T et al. Synoviocyte infection with adeno-associated virus (AAV) is neutralized by human synovial fluid from arthritis patients and depends on AAV serotype. Hum Gene Ther 2007; 18: 525-535.
34. Gouze E, Gouze JN, Palmer GD, Pilapil C, Evans CH, Ghivizzani SC. Transgene persistence and cell turnover in the diarthrodial joint: implications for gene therapy of chronic joint diseases. Mol Ther 2007; 15: 1114-1120.
35. Watanabe S, Imagawa T, Boivin GP, Gao G, Wilson JM, Hirsch R. Adeno-associated virus mediates long-term gene transfer and delivery of chondroprotective IL-4 to murine synovium. Mol Ther 2000; 2: 147-152.
36. Ulrich-Vinther M, Duch MR, Soballe K, O'Keefe RJ, Schwarz EM, Pedersen FS. In vivo gene delivery to articular chondrocytes mediated by an adeno-associated virus vector. J Orthop Res 2004; 22: 726-734.
37. McIlwraith CW, Frisbie DD, Kawcak CE. The horse as a model of naturally occurring osteoarthritis. Bone Joint Res 2012; 1: 297-309.
38. Frisbie DD, Ghivizzani SC, Robbins PD, Evans CH, McIlwraith CW. Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene. Gene Ther 2002; 9: 12-20.
39. Goodrich LR, Hidaka C, Robbins PD, Evans CH, Nixon AJ. Genetic modification of chondrocytes with insulin-like growth factor-1 enhances cartilage healing in an equine model. J Bone Joint Surg Br 2007; 89: 672-685.
40. Morisset S, Frisbie DD, Robbins PD, Nixon AJ, McIlwraith CW. IL-1ra/IGF-1 gene therapy modulates repair of microfractured chondral defects. Clin Orthop Relat Res 2007; 462: 221-228.
41. Catterall JB, Stabler TV, Flannery CR, Kraus VB. Changes in serum and synovial fluid biomarkers after acute injury (NCT00332254). Arthritis Res Ther 2010; 12: R229.
42. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005; 201: 1479-1486.
43. Granowitz EV, Clark BD, Mancilla J, Dinarello CA. Interleukin-1 receptor antagonist competitively inhibits the binding of interleukin-1 to the type II interleukin-1 receptor. J Biol Chem 1991; 266: 14147-14150.
44. Firestein GS, Berger AE, Tracey DE, Chosay JG, Chapman DL, Paine MM et al. IL-1 receptor antagonist protein production and gene expression in rheumatoid arthritis and osteoarthritis synovium. J Immunol 1992; 149: 1054-1062.
45. Arend WP, Malyak M, Guthridge CJ, Gabay C. Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 1998; 16: 27-55.
46. Arend WP. Interleukin-1 receptor antagonist. Adv Immunol 1993; 54: 167-227.
47. Gabay C, Arend WP. Treatment of rheumatoid arthritis with IL-1 inhibitors. Springer Semin Immunopathol 1998; 20: 229-246.
48. Bendele A, McAbee T, Woodward M, Scherrer J, Collins D, Frazier J et al. Effects of interleukin-1 receptor antagonist in a slow-release hylan vehicle on rat type II collagen arthritis. Pharm Res 1998; 15: 1557-1561.
49. Rutgers M, Saris DB, Dhert WJ, Creemers LB. Cytokine profile of autologous conditioned serum for treatment of osteoarthritis, in vitro effects on cartilage metabolism and intra-articular levels after injection. Arthritis Res Ther 2010; 12: R114.
50. Bandara G, Mueller GM, Galea-Lauri J, Tindal MH, Georgescu HI, Suchanek MK et al. Intraarticular expression of biologically active interleukin 1-receptorantagonist protein by ex vivo gene transfer. Proc Natl Acad Sci USA 1993; 90: 10764-10768.
51. Zhang X, Mao Z, Yu C. Suppression of early experimental osteoarthritis by gene transfer of interleukin-1 receptor antagonist and interleukin-10. J Orthop Res 2004; 22: 742-750.
52. Watson RS, Broome TA, Levings PP, Rice BL, Kay JD, Smith AD et al. scAAV-mediated gene transfer of interleukin-1-receptor antagonist to synovium and articular cartilage in large mammalian joints. Gene Ther 2013; 20: 670-677.
53. Wehling P, Reinecke J, Baltzer AW, Granrath M, Schulitz KP, Schultz C et al. Clinical responses to gene therapy in joints of two subjects with rheumatoid arthritis. Human Gene Ther 2009; 20: 97-101.
54. Evans CH, Robbins PD, Ghivizzani SC, Wasko MC, Tomaino MM, Kang R et al. Gene transfer to human joints: progress toward a gene therapy of arthritis. Proc Natl Acad Sci USA 2005; 102: 8698-8703.
55. Mease PJ, Cohen S, Gaylis NB, Chubick A, Kaell AT, Greenwald M et al. Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial. J Rheumatol 2010; 37: 917-927.
56. Goater J, Muller R, Kollias G, Firestein GS, Sanz I, O'Keefe RJ et al. Empirical advantages of adeno associated viral vectors in vivo gene therapy for arthritis. J Rheumatol 2000; 27: 983-989.
57. Gouze E, Pawliuk R, Gouze JN, Pilapil C, Fleet C, Palmer GD et al. Lentiviralmediated gene delivery to synovium: potent intra-articular expression with amplification by inflammation. Mol Ther 2003; 7: 460-466.
58. Evans CH, Ghivizzani SC, Kang R, Muzzonigro T, Wasko MC, Herndon JH et al. Gene therapy for rheumatic diseases. Arthritis Rheum 1999; 42: 1-16.
59. Gray SJ, Matagne V, Bachaboina L, Yadav S, Ojeda SR, Samulski RJ. Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol Ther 2011; 19: 1058-1069.